Leal Therapeutics

A pill that tells an overexcited brain to calm down

Somewhere in a clinic, a person with schizophrenia is taking a small white pill. It is not another dopamine blocker - the class of drugs that has defined psychiatry, and its side effects, for seventy years. It is something stranger. The pill is designed to throttle an enzyme called glutaminase, quieting an over-revved metabolic engine inside neurons. That pill is LTX-001, and it is the clearest expression yet of what Leal Therapeutics actually believes.

Leal is a small company - around 34 people in Worcester, Massachusetts - working on a question that pharma has mostly walked away from. What if the brain's most stubborn diseases are not separate mysteries, but variations on a single theme: a metabolism that has quietly stopped balancing its books?

The brain is an energy hog, and nobody was treating it like one

The brain is about two percent of your body weight and burns roughly twenty percent of your energy. It is, in the most literal sense, a metabolic organ. And yet most CNS drug development has treated brain disease as a wiring problem - too much of this receptor, too little of that signal - while largely ignoring the power supply underneath.

The cost of that blind spot is hard to overstate. Schizophrenia treatments still lean on decades-old mechanisms. ALS remains, with rare exceptions, a death sentence. Alzheimer's has humbled the industry's biggest budgets. The drugs that do exist tend to manage symptoms while the underlying biology keeps marching.

It is a contrarian read of the field. Glutaminase, the enzyme LTX-001 targets, is something oncologists discuss far more often than psychiatrists - it shows up in cancer metabolism papers, not in textbooks on the mind. Borrowing that idea for schizophrenia is the kind of move that sounds reckless until it works.

A neuroscientist who keeps building brain companies

Leal is the encore of Asa Abeliovich, a man with an unusual resume even by biotech standards. Before founding Leal in 2021, he spent years as a tenured professor of pathology, cell biology and neurology at Columbia University, studying the brain from the inside. Then he proved he could turn that science into a company: his startup Prevail Therapeutics was acquired by Eli Lilly in 2021.

Most people would treat a pharma acquisition as a finish line. Abeliovich treated it as a warm-up. With more than 25 years in CNS research behind him, he assembled a leadership bench of seasoned drug developers - a chief medical officer, a chief technology officer, heads of translational science and bioinformatics - and pointed them at the metabolism thesis.

The bet attracted believers. OrbiMed, Newpath Partners and Euclidean Capital backed a $39M seed in 2022. Chugai's venture arm and Alexandria joined later. By 2025, SV Health Investors' Dementia Discovery Fund - a fund that exists specifically to find this kind of swing - was leading the Series A.

One thesis, three molecules, two formats

Leal's pipeline is deliberately diverse in how it intervenes - small molecules and antisense oligonucleotides - but unified in why. Each program targets a metabolic or biochemical pathway that goes wrong in CNS disease.

Four programs, one operating system. The biology underneath is more elegant than the names, which read like spare parts in a catalog.

Money is a vote. Here's the tally.

A thesis this unusual lives or dies on whether serious investors will fund it. Leal has now raised roughly $114M across three events, and the cap table reads like a who's-who of life-science capital. The most telling signal: the 2025 round was led by a fund built specifically to chase dementia breakthroughs.

The investor roster - OrbiMed, Newpath Partners, Chugai Venture Fund, Euclidean Capital, Alexandria Venture Investments, PhiFund and SV Health - matters less for the dollars than for the diligence behind them. And the science gives them something to point to: early clinical data on LTX-001 supporting safety and target engagement, the first proof that the metabolism idea can survive contact with actual patients.

Treating the root, not the symptom

Strip away the enzyme names and the mechanism slides, and Leal's mission is plain: develop first-in-class neuro-metabolic medicines that correct the brain's chemistry for diseases that have, so far, won. The work is grounded in things you can measure - human genetics, biomarker data, preclinical pathways - rather than hope.

There is something quietly radical about treating schizophrenia and ALS as cousins. One is a psychiatric condition, the other a fatal neurodegenerative one. They share almost nothing in how they present. Leal's argument is that they may share a great deal in how they break.

If the metabolism thesis holds

Leal is still early. Clinical-stage biotech is a graveyard of elegant ideas, and a thesis is not a drug. The company has to turn safety and target-engagement signals into actual efficacy, in real patients, in diseases that have defeated far larger players. None of that is guaranteed.

But the upside is the kind that justifies the risk. If correcting brain metabolism really does move the needle in schizophrenia, the same logic could ripple across bipolar disorder, depression, ALS and Alzheimer's - a platform rather than a single shot. That is why a fund dedicated to dementia, and a founder who has done this before, are willing to wait for the readouts.

Back in that clinic, the person with schizophrenia swallows the small white pill. For seventy years, the options on that tray came from one idea about the brain. Leal is betting there is another idea - older than the receptors, written in the brain's metabolism - and that it is finally getting its trial. The pill is the same size as the old ones. What it is trying to fix is not.